Oric gets a reality check
Rinzimetostat efficacy wanes further as the company moves into phase 3.
Allogene looks to consolidate its position
After a delay, the Alpha-3 study faces an April futility analysis.
Karyopharm gets an Xpovio blow
The Sentry trial hits on spleen volume reduction, but misses on symptoms.
AACR 2026 – private biotechs score plenaries
Circle Pharma and Verismo feature in coveted sessions.
Pfizer bags a hormone-sensitive win
Talapro-3 could help move Talzenna into earlier prostate cancer.
AACR 2026 – conjugates remain centre stage
Single, double and even triple-payload ADCs will be presented at the meeting.
